Clinical Trials · NCT02677896
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Astellas Pharma Global Development, Inc.
- Enrollment
- 1,150
- Start date
- Mar 2016
- Locations
- 203 sites, 24 countries
- Primary endpoint
- Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria